Medtronic plc. Ordinary Shares (NYSE:MDT) Encourages Runners To Register For 2017 Global Champions Team


Those who wish to participate in the 2017 Medtronic Global Champions team can start sending in their applications. Medtronic plc. Ordinary Shares (NYSE:MDT) says that the new program will enroll up to 20 people and an additional representation from Twin Cities In Motion. The program will be recognizing athletes who have persisted through life-changing health conditions

Participants must meet certain conditions

Among many other things, the selected individuals will be given a paid entry not only for themselves but also for a running partner. There will also be a complimentary travel package alongside a provision of a host of other VIP events. However, this will not just come on a silver platter.

The selected individuals must meet certain conditions, which will involve a certification from their physicians. Thus they must have discussed the race with them. It is also mandatory that they have a medical device and a therapy that can treat various conditions the likes of stroke, cancer, diabetes, and heart diseases among others.

The program will be arousing people to take action with their health

The 2017 Medtronic Twin Cities Marathon, which will be taking place from September 29 – October 1, 2017, will be an inspiring platform for people with medical conditions. The VP for Medtronic Global Communications and Corporate Marketing, Rob Clark says that the program will help the participants reach out to those living with certain medical circumstances.

He quotes, “By sharing their remarkable stories with the world, we hope to educate, inspire and encourage people to take action with their own health.” The selectees will also be demonstrating the possibility of having an active life regardless of whatever medical circumstances so long one of receiving quality healthcare.

Medtronic, among the world’s largest medical technology companies has had its newest iteration of its CoreValve Evolut transcatheter aortic valve replacement (TAVR) approved by the FDA. The approval came after the company disclosed 30-day data indicating high survival blood flow. This is said to be an outstanding treatment alternative for patients suffering from severe aortic stenosis and cannot stand acute dangers of surgery.

Meanwhile, Medtronic’s stock closed at $80.10 A FALL OF $-0.05 or -0.06%.

An ad to help with our costs